Trials / Completed
CompletedNCT01498302
Comparison of Laboratory Test Results of Minimal-Residual Disease in Samples From Patients With Acute Myeloid Leukemia
Interlaboratory Comparability Study of Residual Disease in Acute Myelogenous Leukemia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (estimated)
- Sponsor
- Children's Oncology Group · Network
- Sex
- All
- Age
- 120 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Diagnostic procedures that find residual disease may help predict if the disease will come back in patients diagnosed with acute myeloid leukemia. PURPOSE: This research trial studies the comparison of laboratory test results for minimal residual disease in samples from patients with acute myeloid leukemia.
Detailed description
OBJECTIVES: * To promote harmonization between Cooperative Group Reference Laboratories conducting minimal-residual disease (MRD) evaluation of acute myeloid leukemia by flow cytometry. OUTLINE: Archived bone marrow and blood samples, distributed to the Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B laboratories, are analyzed for leukemia-associated immunophenotype (LAIP) assays and minimal residual disease studies by flow cytometry. Results are then provided to the National Cancer Institute for assessment and comparability of test results.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | diagnostic laboratory biomarker analysis | |
| OTHER | flow cytometry |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2016-07-01
- First posted
- 2011-12-23
- Last updated
- 2016-07-11
Source: ClinicalTrials.gov record NCT01498302. Inclusion in this directory is not an endorsement.